LENZ Stock Forecast: LENZ Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$3.21

The 6 Wall Street analysts covering LENZ Therapeutics, Inc. hold a median 12-month price target of $9.5 — +196.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 22 of 100 as at 18 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$104.9M
Ticker Nerd rank
22/ 100
Median analyst target
$9.50
Analysts covering
6
Revenue$5.5M+9.7% y/y
Operating income−$34.2M
Net income−$31.9M
Free cash flow−$38.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores LENZ Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
22/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
65
Volatility
56
Accruals
54
Issuance
37
Quality
36
Value
13
Growth
13
Momentum
2

Revisions (65): Analysts have, on balance, been raising their forecasts.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LENZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LENZ, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says6 analysts
4
Buy
2
Hold
0
Sell
$4.00
Low
$9.50
Median
$45.00
High

The green dot is the last close — the median target sits +196.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
5 Nov 2026CitigroupMaintainsBuy$10 → $9.00
30 Oct 2026HC Wainwright & Co.MaintainsBuy$38 → $16
29 Oct 2026TD CowenMaintainsBuy$50 → $45
21 Oct 2026TD CowenMaintainsBuy$60 → $50
19 Oct 2026Piper SandlerMaintainsNeutral$7.00 → $5.00
12 Aug 2026Piper SandlerMaintainsNeutral$12 → $7.00
7 July 2026HC Wainwright & Co.ReiteratesBuy$38
13 May 2026CitigroupMaintainsBuy—
12 May 2026HC Wainwright & Co.MaintainsBuy—
12 May 2026Piper SandlerDowngradeNeutral—
21 Apr 2026HC Wainwright & Co.MaintainsBuy—
26 Mar 2026CitigroupMaintainsBuy—
25 Mar 2026B of A SecuritiesMaintainsBuy—
20 Oct 2025Raymond JamesReiteratesOutperform—
10 Oct 2025Piper SandlerMaintainsOverweight—
1 Aug 2025CitigroupMaintainsBuy—
1 Aug 2025HC Wainwright & Co.MaintainsBuy—
31 July 2025CitigroupMaintainsBuy—
31 July 2025Raymond JamesMaintainsOutperform—
28 July 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LENZ.

Market Radar

This page is one stock. Monday covers all of them.

LENZ appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

LENZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
8.5×

Cheaper than 14% of US stocks

Price / book
0.5×

Cheaper than 86% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
94.9%

Higher than 98% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−72.7%

Higher than 17% of US stocks

Return on assets
−44.5%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • LENZ Therapeutics, Inc. has a market value of $104.9M.

  • Revenue in the twelve months to 30 June 2026: $21.5M. The latest quarter grew 9.7% year on year.

  • Net income over the same four quarters: −$126.0M, a −586.7% net margin.

  • Diluted earnings per share, trailing twelve months: −$4.09.

  • Free cash flow in the twelve months to 30 June 2026: −$114.4M.

  • Shares outstanding: 31.4M.

  • LENZ Therapeutics, Inc. employs 40 people — $537K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

LENZ and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LENZLENZ Therapeutics, Inc.$104.9M22
VYGRVoyager Therapeutics, Inc.$99.5M61
ICCCImmuCell Corp.$102.3M94
OTLKOutlook Therapeutics, Inc.$99.3M3
TLSATiziana Life Sciences Ltd. (Bermuda)$103.7M25
UNCYUnicycive Therapeutics, Inc.$104.2M36
CBUSCibus, Inc.$104.4M27

Take a look at LENZ’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own LENZ Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LENZ

What is the LENZ stock price forecast for 2026-2027?

The 6 Wall Street analysts covering LENZ Therapeutics, Inc. have a median 12-month price target of $9.5, with estimates ranging from $4 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LENZ stock a buy right now?

Of the 6 analysts covering LENZ Therapeutics, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LENZ Therapeutics, Inc. 22 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LENZ?

As at 18 Nov 2026, LENZ Therapeutics, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (65 of 100).

Will LENZ stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +196.0% from the last close, and Ticker Nerd's factor model ranks LENZ Therapeutics, Inc. 22 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LENZ stock forecast for 2030?

No analyst covering LENZ Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LENZ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $45 over the next 12 months.

What does LENZ Therapeutics, Inc. do?

LENZ Therapeutics, Inc. is a pharmaceutical and biotechnology company focused on commercializing ophthalmic treatments that improve vision. Its primary product is VIZZ, an aceclidine-based eye drop approved for the treatment of presbyopia, the age-related loss of near vision.

Company

About LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. is a pharmaceutical and biotechnology company focused on commercializing ophthalmic treatments that improve vision. Its primary product is VIZZ, an aceclidine-based eye drop approved for the treatment of presbyopia, the age-related loss of near vision. The company develops eye-care therapies designed for convenient daily use, with an emphasis on preservative-free, single-use formulations that support patient adherence and ease of administration. LENZ Therapeutics serves the prescription eye-care market and concentrates on addressing a common vision condition affecting adults worldwide. Headquartered in Solana Beach, California, the company plays a specialized role in the broader ophthalmology and biopharmaceutical sectors by bringing non-surgical treatment options to market for presbyopia management.

CEO Mr. Evert B. Schimmelpennink · 40 employees · United States · https://www.lenz-tx.com